Precision for Medicine and Trialbee Partner to Advance Clinical Trials for Complex Therapies and Speed Shift Toward Precision Medicine
Clinical research organization Precision for Medicine and Trialbee, a patient matching and enrollment platform, are addressing complexities in clinical development through a new partnership that will accelerate the future of precision medicine. Trialbee’s advanced analytics will play a critical role in matching patients to trials conducted by Precision for Medicine and extending recruitment to a more diverse, targeted patient community for the development of complex, personalized medicine.
The partnership expands Precision for Medicine’s ability to match patients who could benefit from life-saving therapies, especially those who could be a match for trials in oncology, rare and orphan diseases, including cell or gene therapy trials. Trialbee enables accurate and fast enrollment, improving the patient journey and helping to meet patient enrollment timelines.
The Precision Site Network, which includes both academic and non-academic sites across North America, Europe, and Australia, can combine with Trialbee’s targeting data to identify untapped populations for trials. This outreach, which can be geotargeted to trial candidates close to that site, greatly enhances patient enrollment with a focus on representative trial participants.
Trialbee HIVE™ is a real-world data-driven patient matching platform that accelerates recruitment using global data assets, look-alike modeling, and digital outreach. Then, interested participants are qualified and enrolled through a nurse qualification process and patient centric experience.
Both companies are industry leaders in applying technology and data science to help clinical research sponsors succeed in the development of life-changing therapies. Precision has comprehensive study experience in complex therapeutic area and a converged approach to development that includes seamless operations between labs, data, and trials.
“We are working with life science innovators who share a passion to connect next generation treatments with the patients who need them most,” said Precision for Medicine President, Chad Clark. “This partnership expands our ability to reach more patients, faster; particularly those with rare or difficult-to-treat diseases.”
Precision for Medicine and Trialbee also reduce the burden on patients and sites. Trialbee’s patient data, which is HIPPA compliant, includes socioeconomic data as well as clinical data, enabling better characterization of the patient population. This helps Precision for Medicine forecast situations in which decentralized clinical trial approaches may be implemented to accommodate work schedules or when the use of free transportation services to and from the site can increase enrollment and retention.
“Our combined capabilities support a patient-first approach that will expand diversity, bolster enrollment, and speed the development of new therapies for complex diseases,” said Trialbee’s CEO, Matt Walz. “Our ability to bring more transparency and easy communication to the well-established Precision framework improves the potential for life-saving drugs to get to market and improve patient outcomes.”
About Precision for Medicine
Precision for Medicine is the first biomarker-driven clinical research services organization supporting life sciences companies in the use of biomarkers essential to targeting patient treatments more precisely and effectively. Precision applies novel biomarker approaches to clinical research that integrate clinical trial execution with deep scientific knowledge, laboratory expertise and advanced data sciences. This convergence of trials, labs and data sciences is driving faster clinical development and approval. Precision for Medicine is part of Precision Medicine group with over 2,500 people in 35 locations in the U.S., Canada, and Europe. For more information, visit http://www.precisionformedicine.com.
About Trialbee
Trialbee is the leading global data and technology platform for patient matching and enrollment in clinical trials. Trialbee Hive™ operationalizes real world data (RWD) and applies data science to match patients globally. Our Candidate Manager platform simplifies the journey for matched patients to qualify and participate in clinical research. Partnering with Sponsors, CROs and virtual/decentralized sites and software providers, Trialbee is achieving patient enrollment goals and driving enhancements in diversity in clinical trial populations. We are the smartest way to match and enroll patients for your clinical trial. For more information, visit http://www.trialbee.com or contact us at solutions@trialbee.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210805005145/en/
Contact information
Rosina Ferrante
Gregory FCA (for Trialbee)
215-344-2113
rosina.ferrante@trialbee.com
Louis Landon
Precision Medicine Group
310 984 7707
louis.landon@precisionvh.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pingo Doce Sets New Standard for AI-Driven Merchandising with SymphonyAI—and Raises the Bar for CPG Collaboration14.10.2025 07:06:00 EEST | Press release
Pingo Doce is moving fast to redefine merchandising with AI—replacing static reports with real-time, prescriptive insights that fuel sharper execution and stronger supplier alignment. The Portuguese retailer is part of Jerónimo Martins, one of Europe’s largest food retailers with over 5,700 stores across Portugal, Poland, and Colombia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251013626268/en/ Instead of static dashboards or flat-file reports, suppliers now get direct access to actionable intelligence. CPG partners can run dynamic “what-if” scenarios, optimize promotions and assortments, and see projected revenue impacts—collaborating in real time with Pingo Doce category teams. Powered by SymphonyAI’s CINDE Connected Retail platform, Pingo Doce is combining POS, assortment and shelf data into a single intelligent layer. The result: a modern monetizable insights platform that delivers next-best actions for both internal
Comcast Technology Solutions and Deutsche Telekom Partner to Deliver Advanced Whole-Home WiFi in Europe14.10.2025 07:00:00 EEST | Press release
Comcast Technology Solutions (CTS), a division of Comcast delivering media and connectivity innovations globally, today announced a major collaboration with Deutsche Telekom (DT) to introduce cutting-edge, whole-home WiFi Mesh technology in Europe. This strategic partnership brings together Comcast’s cloud-based WiFi Mesh Platform, already deployed at scale in North America and Europe, with DT’s European market strength, to provide seamless, intelligent connectivity across the home. The solution enables customers to enjoy reliable, self-optimising WiFi coverage that adapts dynamically to device usage and home layouts. "As expectations for seamless in-home connectivity continue to grow, we're focused on delivering high-performance, reliable solutions that meet those needs,” said Pedro Bandeira, Senior Vice President of Product and New Business at Deutsche Telekom. “Comcast’s proven technology supports our vision for future-ready broadband." A WiFi Solution Built for Reliability, Innovat
Abu Dhabi Unveils World’s First AI Public Servant at GITEX Global 202514.10.2025 01:23:00 EEST | Press release
Abu Dhabi is unveiling the world’s first AutoGov function with the latest version of TAMM today at GITEX Global 2025. AutoGov automatically manages recurring tasks — from license renewals and utility payments to scheduling routine healthcare appointments — running in the background of daily life so that people have more time to do the things they love and never have to worry about routine services. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251013919760/en/ His Excellency Ahmed Tamim Hisham Al Kuttab, Chairman of the Department of Government Enablement – Abu Dhabi (DGE) (Photo: AETOSWire) The TAMM AutoGov function launch takes service delivery to the next level, marking a pivotal milestone in Abu Dhabi’s journey to becoming the world’s first AI-native government, representing the next generation of integrated intelligent service delivery. It can automatically manage recurring services, with users having the ability to se
Cessna Citation M2 Gen2 with Garmin Autothrottles Achieves FAA Certification, Bringing Greater Control and Precision to Pilots14.10.2025 01:00:00 EEST | Press release
The Cessna Citation M2 Gen2 with Garmin Autothrottles recently received certification from the Federal Aviation Administration (FAA), bringing greater control and precision to pilots. The integration of Garmin’s Autothrottle system in the M2 Gen2 further supports the most delivered light-entry jet’s capabilities by optimizing engine power, simplifying flight management and increasing overall operating efficiency. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251013861341/en/ Cessna Citation M2 Gen2 with Garmin Autothrottles achieves FAA certification, bringing greater control and precision to pilots (Photo Credit: Textron Aviation). The Cessna Citation M2 Gen2 is designed and produced by Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company. The flight test program for the Citation M2 Gen2 with autothrottles completed nearly 300 flight test hours and numerous certification tests, adhering to stringent certification stan
Cessna Citation CJ3 Gen2 achieves FAA type certification, bringing the most comprehensive Gen2 enhancements to market14.10.2025 01:00:00 EEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, announced the Cessna Citation CJ3 Gen2 has achieved Federal Aviation Administration (FAA) type certification, bringing the most comprehensive Citation Gen2 investment to market. Based on customer feedback, enhancements throughout the aircraft include Garmin autothrottle technology, an additional 4.5 inches of legroom for pilots and a fully customizable cabin environment. After completing 445 flight test hours, the light jet is expected to enter into service this year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251013311527/en/ Cessna Citation CJ3 Gen2 achieves FAA type certification, bringing the most comprehensive Gen2 enhancements to market (Photo Credit: Textron Aviation). “FAA certification of the CJ3 Gen2 is an example of Textron Aviation’s leadership in certifying aircraft,” said Chris Hearne, senior vice president, Engineering & Programs. “This aircraft de
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom